ganesh raj’s Post

Anti- CEACAM6 antibody+ BET protein degrader conjugate inhibits tumour growth in pancreatic cancer models. https://lnkd.in/g43BaqPm

Comparative Effectiveness of First-Line Treatments for Metastatic Castration-Resistant Prostate Cancer This study compares the effectiveness of poly ADP-ribose polymerase inhibitors

#ASCO is already a treasure trove of incredible cell therapy clinical data! "AIC100 Phase 1 study is the first known complete response following a single IV dose of autologous CAR T cells observed in any solid tumor cancer type" These results represent a paradigm shift in therapeutic options for patients with #solidtumors. CAR-T is slowly validating itself as a viable option for solid tumor treatment https://lnkd.in/eVcnpkvZ

Eisai Co., Ltd.'s DAC Research 1. Delivering EBET using the CEACAM6 antibody degrades BRD (bromodomain proteins) in CEACAM6-positive pancreatic cancer cells. 2. They regulate pancreatic cancer stromal signaling through a bystander effect on CEACAM6-negative CAFs (cancer-associated fibroblasts). STAT3, a key signaling molecule in CAFs, is functionally linked to BRD2/4, and EBET payloads diffused from pancreatic cancer cells inhibit STAT3 signaling in CAFs. 3. The #84.7 antibody has a lower binding affinity to normal cells like MPCs (myeloid progenitor cells) than existing CEACAM6 antibodies, reducing side effects on normal cells.

An excellent 𝑵𝒂𝒕𝒖𝒓𝒆 𝑪𝒐𝒎𝒎𝒖𝒏𝒊𝒄𝒂𝒕𝒊𝒐𝒏𝒔 paper by Youya Nakazawa et al. describing yet another innovative ADC structure. In the paper the authors show preclinical efficacy in a pancreatic cancer model of an ADC composed of a BET protein-degrader 'warhead' conjugated to an anti-CEACAM6 antibody. https://lnkd.in/eUK_P294

A consortium of pancreatic cancer researchers is sharing informations that has shown that an oral inhibitor, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells. In this article we will know about this discovery that holds the promise of improving the prognosis for patients with PDAC and potentially other cancers with RAS mutations, marking a hopeful step forward in oncology. https://lnkd.in/dutEEDNt #pancreaticcancer, #clincaltrials

When there's a new line of treatment, I usually wait for expert opinion and recommendations before starting using it, Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer is not a new combination, because of the long time for debate, I didn't start to use it, This article is one of the best articles that help solve this debate. Thanks for the authors Hirotsugu Kenmots. American Society of Clinical Oncology (ASCO) #Lung cancer #Osimertinib #VEGF

Invikafusp alfa alone led to clinical activity in cancers with high tumor mutation burden including confirmed responses in microsatellite stable colorectal cancer, according to findings from the ongoing phase 1/2 START-001 trial. #crcsm https://lnkd.in/ed_9ZEqE

The inability of cells to kill themselves is directly linked to both the development of cancer, and resistance to therapy. The major advances in mapping of cell death-associated signalling pathways that led to venetoclax being approved for use in the clinic – and an explosion of associated clinical trial activity – have now firmly established the pharmacological targeting of cell death pathways, including apoptosis and autophagy, as a crucial therapeutic approach in cancer treatment. Our infographic maps the signalling cascades involved in apoptosis and autophagy – highlighting major targets of drug intervention, highly sought-after therapeutic strategies and ongoing clinical trials. Check out the free infographic to learn more: https://okt.to/BFYwWU #Infographic #CellDeath #apoptosis #CancerResearch #ResearchChemicals

Aptamer-drug conjugates (ApDC) + bacteria delivery vehicle presents an effective synergistic pancreatic cancer treatment strategy: https://lnkd.in/gXCMNARh